In.pact™ av drug-coated balloon is first and only to show superior and sustained results through two years compared to pta in treating arteriovenous fistulae lesions

In.pact av access trial 24 month results presented as a podium first at charing cross symposium dublin and london, april 20, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the in.pact av access clinical study. the data, which were presented virtually as a podium first at the 2021 charing cross symposium, demonstrated that the in.pact™ av drug-coated balloon (dcb) is the first and only dcb to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (pta) in end-stage renal disease (esrd) patients with de novo or non-stented restenotic native arteriovenous fistulae (avf) in the upper extremity.1,2 "a patient who receives hemodialysis will often need to have several reinterventions each year to maintain patency and keep critical access sites open and functioning properly," said andrew holden, mbchb, franzcr, director of interventional radiology at auckland hospital and associate professor of radiology at auckland university.
MDT Ratings Summary
MDT Quant Ranking